New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
10:03 EDTATR, TEN, SFUN, MRVL, MRO, IPSEY, FNSR, CSH, CCG, BLL, LULUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AptarGroup (ATR) downgraded to Underperform from Neutral at BofA/Merrill... Ball Corp. (BLL) downgraded to Neutral from Buy at BofA/Merrill... Campus Crest (CCG) downgraded to Underperform from Neutral at BofA/Merrill... Cash America (CSH) downgraded to Market Perform at FBR Capital... Finisar (FNSR) downgraded to Hold from Buy at Craig-Hallum... Ipsen (IPSEY) downgraded to Neutral from Overweight at JPMorgan... Marathon Oil (MRO) downgraded to Market Perform from Outperform at Wells Fargo... Marvell (MRVL) downgraded at Susquehanna... Rackspace (RAX) downgraded to Underperform from Neutral at DA Davidson... SouFun (SFUN) downgraded to Neutral from Overweight at JPMorgan... Tenneco (TEN) downgraded to Hold from Buy at Deutsche Bank... lululemon (LULU) downgraded to Neutral from Overweight at JPMorgan.
News For ATR;BLL;CCG;CSH;FNSR;IPSEY;MRO;MRVL;SFUN;TEN;LULU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
06:37 EDTCSHStates relax personal loan restrictions, NY Times says
Subscribe for More Information
05:17 EDTIPSEYIpsen, Lexicon enter into ex-North America/Japan licensing agreement
Ipsen (IPSEY) and Lexicon Pharmaceuticals (LXRX) announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan. Lexicon is conducting Phase 3 clinical trials of telotristat etiprate for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Carcinoid syndrome is characterized by severe diarrhea, flushing and, in some cases, heart valve damage. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase, or TPH, that reduces peripheral serotonin production without affecting brain serotonin levels. Telotristat etiprate has received fast track status and orphan drug designation from the FDA, and has received orphan drug designation from the European Medicines Agency. Under the financial terms of the agreement, Lexicon is eligible to receive up to $145M, comprising $23M upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones. In addition, Lexicon is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.
04:57 EDTLULUlululemon partners with Dalai Lama Center
Subscribe for More Information
October 21, 2014
10:00 EDTTENOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:27 EDTTENTenneco initiated with a Positive at Susquehanna
Target $61.
October 16, 2014
10:01 EDTLULUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Akamai (AKAM) downgraded to Market Perform from Outperform at Wells Fargo... CGG SA (CGG) downgraded to Reduce from Neutral at Nomura... Central Valley Community (CVCY) downgraded to Hold from Buy at Sandler O'Neill... DSM (RDSMY) downgraded to Neutral from Buy at Nomura... Disney (DIS) downgraded at Guggenheim... Francesca's (FRAN) downgraded to Underperform from Outperform at Macquarie... Netflix (NFLX) downgraded to Fair Value from Buy at CRT Capital... Nordstrom (JWN) downgraded to Neutral from Outperform at Macquarie... Norfolk Southern (NSC) downgraded at Credit Suisse... Rio Tinto (RIO) downgraded to Market Perform at Cowen... Seadrill (SDRL) downgraded to Reduce from Neutral at Nomura... Ternium (TX) downgraded to Neutral from Overweight at JPMorgan... Urban Outfitters (URBN) downgraded to Neutral from Outperform at Macquarie... Viacom (VIAB) downgraded at BofA/Merrill... eBay (EBAY) downgraded to Underperform from Buy at CLSA... lululemon (LULU) downgraded to Underperform from Neutral at Macquarie.
08:14 EDTMROInternational E&P price targets lowered at Wells Fargo
Subscribe for More Information
05:39 EDTLULUlululemon downgraded to Underperform from Neutral at Macquarie
Macquarie downgraded lululemon to Underperform after assuming coverage of the stock saying the company's expansion into Asia and Europe will drive a meaningful increase in spending. The firm lowered its price target for shares to $34 from $40.
October 15, 2014
17:22 EDTMROMarathon Oil receives about $2.1B from sale of Norway business
Subscribe for More Information
07:36 EDTMROMarathon Oil volatility at three-year high as WTI Crude trades below $82
Subscribe for More Information
October 13, 2014
14:02 EDTLULUlululemon's Q3 sales tracking below consensus, says ITG Research
Subscribe for More Information
10:08 EDTSFUNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:08 EDTSFUNSouFun upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
October 10, 2014
11:33 EDTIPSEYIpsen announces positive Phase III results for Decapeptyl
Ipsen announced positive results from the phase III study of Decapeptyl administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology 14th Central European Meeting in Cracow, Poland. The primary objective of the study was to assess the efficacy and safety profile of the sustained-release Decapeptyl formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer. This objective was met with castration levels of testosterone achieved in 97.6% of men at week 4 and castration maintained in 96.6% of these men at week 26. The efficacy results and safety profile of Decapeptyl administered by the subcutaneous route are consistent with the known efficacy and safety profile of Decapeptyl administered by the intramuscular route. Based on these results, Ipsen has applied for the addition of the subcutaneous route, alongside the intramuscular route, to the label of Decapeptyl.
10:09 EDTMRVLMarvell management to meet with JPMorgan
Subscribe for More Information
October 9, 2014
06:10 EDTLULUStocks with implied volatility below IV index mean; NKE LULU
Subscribe for More Information
October 8, 2014
10:00 EDTMRVL, CSHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:42 EDTMRVLMarvell initiated with a Buy at Ladenburg
Subscribe for More Information
07:18 EDTCSHCash America initiated with a Neutral at Macquarie
Subscribe for More Information
06:00 EDTLULUStocks with implied volatility below IV index mean; ADHD LULU
Stocks with implied volatility below IV index mean; Alcobra (ADHD) 123, lululemon (LULU) 35 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use